Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 2/20 | 0.48 |
| ▸ | HTR1B | P28222 | 2/20 | 0.47 |
| ▸ | LSS | P48449 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4711565 | 0.82 | HTR1B (0.45) | HRH1HTR1BLSSKDM4E | |
| SCHEMBL1906166 | 0.76 | EGFR (0.52) | — | |
| SCHEMBL4715746 | 0.74 | ALDH1A1 (0.44) | HRH1HTR1BKDM4E | |
| SCHEMBL4717150 | 0.73 | ALDH1A1 (0.41) | HRH1HTR1BKDM4E | |
| SCHEMBL22552118 | 0.73 | HTR7 (0.49) | HTR1BKDM4EHTR7 | |
| SCHEMBL15883729 | 0.71 | TOP2A (0.49) | HTR1BLSSKDM4E | |
| SCHEMBL4714333 | 0.70 | KDM4E (0.45) | KDM4E | |
| SCHEMBL4710329 | 0.70 | CYP1A2 (0.46) | HTR1B | |
| SCHEMBL1100857 | 0.70 | MAPT (0.62) | HTR1BKDM4E | |
| SCHEMBL1477065 | 0.70 | JAK2 (0.62) | HRH1HTR1BLSSKDM4EHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0998459-B1 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 2008-04-23 | — | — | EP | claimed |
| EP-0998459-A2 | PYRIDINE DERIVATIVES | Novartis AG (CH) | 2000-05-10 | — | — | EP | claimed |
| WO-1999002497-A2 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 1999-01-21 | — | — | WO | claimed |
| EP-0998459-B1 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 2008-04-23 | — | — | EP | disclosed |
| US-6656957-B1 | Marked and selective modulating, especially antagonistic, action at human metabotropic glutamate receptors (mGluRs); treatment of disorders such as epilepsy, cerebral ischemias, especially acute ischemias, spasticity etc. | NOVARTIS AG (CH) | 2003-12-02 | — | — | US | disclosed |